CorMedix Inc (CRMD)

Currency in USD
11.640
-0.030(-0.26%)
Closed·
After Hours
11.639-0.001(-0.01%)
·
CRMD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 4 days
Fair Value
Day's Range
11.15011.675
52 wk Range
3.61017.430
Key Statistics
Prev. Close
11.67
Open
11.47
Day's Range
11.15-11.675
52 wk Range
3.61-17.43
Volume
1.63M
Average Volume (3m)
2.13M
1-Year Change
175.83%
Book Value / Share
1.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.143
Upside
+64.46%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

CorMedix Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

CorMedix Inc Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Employees
65

CorMedix Inc SWOT Analysis


DefenCath's Triumph
CorMedix's stock soars 131% as DefenCath launch in hemodialysis market shows promising early adoption, with significant outpatient pull-through from small and mid-sized operators.
Strategic Partnerships
Explore CorMedix's commercial agreements with dialysis providers, including one LDO and two MDOs, and potential negotiations with a top U.S. dialysis provider.
Financial Trajectory
Delve into CorMedix's Q3 revenues of $5M and EBITDA outlook, with analyst price targets ranging from $11 to $19 per share and a consensus "Buy" recommendation.
Growth Horizons
Learn about CorMedix's expansion plans for DefenCath beyond hemodialysis, targeting total parenteral nutrition and pediatric hemodialysis markets for future growth.
Read full SWOT analysis

CorMedix Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $0.32, doubling forecast; revenue at $39.1M, surpassing expectations by $6.75M
  • Stock rose 6.3% premarket to $9.599; net income of $20.6M vs. $14.5M loss in Q1 2024
  • Revised H1 2025 net revenue guidance to ~$70M; targeting FDA approval for new indication by late 2027
  • Strong performance attributed to DefendCath momentum and strategic market expansions
  • Analysts maintain Strong Buy consensus; stock targets range from $12 to $19 per share
Last Updated: 06/05/2025, 14:34
Read Full Transcript

Compare CRMD to Peers and Sector

Metrics to compare
CRMD
Peers
Sector
Relationship
P/E Ratio
50.4x−3.1x−0.5x
PEG Ratio
0.390.020.00
Price/Book
7.5x2.2x2.6x
Price / LTM Sales
10.5x2.1x3.3x
Upside (Analyst Target)
71.8%171.1%45.4%
Fair Value Upside
Unlock23.3%7.7%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 19.143
(+64.46% Upside)

Earnings

Latest Release
May 06, 2025
EPS / Forecast
0.30 / 0.16
Revenue / Forecast
39.10M / 32.35M
EPS Revisions
Last 90 days

CRMD Income Statement

People Also Watch

107.56
CRDO
-3.58%
13.58
OSCR
-3.35%
52.460
ASTS
-1.34%
208.33
LEU
-3.28%
168.10
CRCL
-8.40%

FAQ

What Stock Exchange Does CorMedix Trade On?

CorMedix is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for CorMedix?

The stock symbol for CorMedix is "CRMD."

What Is the CorMedix Market Cap?

As of today, CorMedix market cap is 866.36M.

What Is CorMedix's Earnings Per Share (TTM)?

The CorMedix EPS (TTM) is 0.28.

When Is the Next CorMedix Earnings Date?

CorMedix will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is CRMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has CorMedix Stock Split?

CorMedix has split 1 times.

How Many Employees Does CorMedix Have?

CorMedix has 65 employees.

What is the current trading status of CorMedix (CRMD)?

As of 03 Aug 2025, CorMedix (CRMD) is trading at a price of 11.64, with a previous close of 11.67. The stock has fluctuated within a day range of 11.15 to 11.68, while its 52-week range spans from 3.61 to 17.43.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.